Effect of Mirabegron on ureteral stent-related symptoms
YANG Jianghua1 LIAO Xiaoxing2 ZHAO Yanpeng1 CUI Gongjing1
1.Department of Urology, Beijing Aerospace General Hospital, Beijing 100076, China;
2.Department of Urology, Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing 100029, China
Abstract：Objective To study the effect of Mirabegron on ureteral stent-related symptoms (SRSs). Methods From January to December 2019, 120 cases with indwelling ureteric stents after surgery for upper urinary tract calculi were selected as research subjects. They were divided into the study group and the control group according to random number table method, with 60 cases in each group. The study group was treated with Mirabegron, while the control group did not use any drugs for lower urinary tract symptoms. At the time of stent removal, the international prostate symptom score (IPSS), quality of life (QoL) score, patient perception of bladder condition (PPBC) score, visual analog scale (VAS) score and the amount of analgesics were compared between the two groups. Results Excluded the cases that lost to follow-up or received other treatment options, 102 cases completed the study: 50 cases in the study group, 52 cases in the control group. At the time of stent removal, the scores of IPSS (storage symptoms), QoL, PPBC, VAS and the amount of analgesics in the study group were lower than those in the control group, and the differences were statisticaliy significant (P < 0.05); there was no significant difference in the score of IPSS (voiding symptoms) between the two groups (P > 0.05). Conclusion Mirabegron has obvious effect on the treatment of SRSs, which can reduce the symptoms of bladder irritation and the amount of analgesic usage.
[1] Sali GM，Joshi HB. Ureteric stents：Overview of current clinical applications and economic implications [J]. Int Urol，2020，27（1）：7-15.
[2] Camtosun A，Bicer S. The impact of Double J stent on the quality of sexual life and job performance [J]. Clin Exp Obstet Gynecol，2020，47（2）：199-201.
[3] Betschart P，Zumstein V，Piller A，et al. Prevention and treatment of symptoms associated with indwelling ureteral stents：A systematic review [J]. Int Urol，2017，24（4）：250-259.
[4] Chapple CR，Cruz F，Cardozo L，et al. Safety and Efficacy of Mirabegron：Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron，Antimuscarinics，or Placebo [J]. Eur Urol，2020，77（1）：119-128.
[5] 许克新，汪磊，王晓峰，等.膀胱过度活动症症状评分表对中国OAB患者结果评估的重复信度及与其他症状评分工具间相关性的研究[J].中华泌尿外科杂志，2010， 31（11）：727-731.
[6] Coyne KS，Matza LS，Kopp Z，et al. The validation of the patient perception of bladder condition（PPBC）：a single-item global measure for patients with overactive bladder [J]. Eur Urol，2006，49（6）：1079-1086.
[7] Delgado DA，Lambert BS，Boutris N，et al. Validation of Digital Visual Analog Scale Pain Scoring With a Traditional Paper-based Visual Analog Scale in Adults [J]. Am Acad Orthop Surg Glob Res Rev，2018，2（3）：e088.
[8] Scotland KB，Lo J，Grgic T，et al. Ureteral stent-associated infection and sepsis：pathogenesis and prevention：a review [J]. Biofouling，2019，35（1）：117-127.
[9] Fischer KM，Louie M，Mucksavage P. Ureteral Stent Discomfort and Its Management [J]. Curr Urol Rep，2018，19（8）：64.
[10] Koprowski C，Kim C，Modi PK，et al. Ureteral Stent-Associated Pain：A Review [J]. Endourol，2016，30（7）：744-753.
[11] 肖世伟，李亚楠，刘军，等.可降解输尿管支架管的研究进展[J].中华泌尿外科杂志，2018，39（1）：76-78.
[12] Wiesinger CG，Lee J，Herrera-Caceres JO. Future developments in ureteral stents [J]. Curr Opin Urol，2019，29（2）：124-128.
[13] Chen YB，Gao L，Jiang Q，et al. Tamsulosin Monotherapy Is Effective in Reducing Ureteral Stent-related Symptoms：A Meta-analysis of Randomized Controlled Studies [J]. Curr Med Sci，2019，39（5）：707-718.
[14] Deliveliotis K，Papatsoris AG，Skolarikos A，et al. Management of stent-related symptoms with the use of α-blockers：A meta-analysis [J]. Arab Urol，2020，18（1）:14-21.
[15] Manjunatha R，Pundarikaksha HP，Madhusudhana HR，et al. A randomized，comparative，open-label study of efficacy and tolerability of alfuzosin，tamsulosin and silodosin in benign prostatic hyperplasia [J]. Indian Pharmacol，2016，48（2）：134-140.
[16] Sivalingam S，Streeper NM，Sehgal PD，et al. Does Combination Therapy with Tamsulosin and Tolterodine Improve Ureteral Stent Discomfort Compared with Tamsulosin Alone？A Double-Blind，Randomized，Controlled Trial [J]. Urol，2016，195（2）：385-390.
[17] Kim A，Lee KS，Jung R，et al. Health Related Quality of Life in Patients with Side-Effects after Antimuscarinic Treatment for Overactive Bladder [J]. Low Urin Tract Symptoms，2017，9（3）：171-175.
[18] Kelleher C，Hakimi Z，Zur R，et al. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder：A Systematic Review and Network Meta-analysis [J]. Eur Urol，2018，74（3）：324-333.
[19] Matsumoto R，Otsuka A，Suzuki T，et al. Expression and functional role of β3 -adrenoceptors in the human ureter [J]. Int Urol，2013，20（10）：1007-1014.
[20] Shen H，Chen Z，Mokhtar AD，et al. Expression of β-adrenergic receptor subtypes in human normal and dilated ureter [J]. Int Urol Nephrol，2017，49（10）：1771-1778.
[21] Matsukawa Y，Takai S，Funahashi Y，et al. Urodynamic evaluation of the efficacy of mirabegron on storage and voiding functions in women with overactive bladder [J]. Urology，2015，85（4）：786-790.
[22] Mandpe P，Prabhakar B，Shende P. Potential of Mirabegron and its Extended-release Formulations for the Treatment of Overactive Bladder Syndrome [J]. Curr Drug Metab，2020，21（2）：79-88.
[23] Solakhan M，Bayrak O，Bulut E. Efficacy of mirabegron in medical expulsive therapy [J]. Urolithiasis，2019，47（3）：303-307.
[24] Urkmez A，Tokuc E，Topaktas R，et al. Mirabegron：A Novel and Promising Medical Expulsive Treatment for Ureteral Stones？ [J]. Coll Physicians Surg Pak，2019，29（1）：73-74.
[25] 唐庆来，吕建林，贾春萍，等.萘哌地尔与曲司氯铵治疗远端输尿管结石伴膀胱过度活动样症状的疗效研究[J].东南大学学报：医学版，2018，37（5）：900-903.
[26] Taguchi M，Yoshida K，Sugi M，et al. Effect of ureteral stent diameter on ureteral stent-related symptoms [J]. Low Urin Tract Symptoms，2019，11（4）：195-199.
2020, Vol. 17 
京公网安备 11010502046598号